Prihlásiť sa Zaregistrujte sa zadarmo

Last updated: 26 August 2024 at 5:36pm EST

John Hubbard Net Worth



John Hubbard biography

Dr. John W. Hubbard Ph.D. serves as Independent Director of the Company. Dr. Hubbard currently serves on the Strategic Advisory Board of Genstar Capital and is responsible for advising the private equity firm on investments in the area of healthcare. He also serves as a non-Executive Director on the Board of Directors of Bracket-CRF Health, a privately-owned specialty clinical trials and technology service provider. Dr. Hubbard was President and the Chief Executive Officer of Bioclinica, a leading privately-owned provider of medical imaging, clinical technology and research services until January 1, 2018. Prior to joining BioClinica, he was Senior Vice President and Worldwide Head of Development Operations for Pfizer Inc. and was responsible for the global clinical trial operations and management of more than 450 clinical projects from Phase I to IV. He was a founding member of the Board of Directors of TransCelerate Biopharma, Inc., a leading biopharma industry consortium, and served on the Executive, Audit and Finance Committees. Dr. Hubbard has been leading pharmaceutical research and development activity for over thirty years and held positions of increasing responsibility in the biopharmaceutical and clinical research and development services industries. Prior to joining Pfizer in 2010, he was Group President, Global Clinical Research Services at ICON Clinical Research, a leading global clinical research organization, where he was responsible for the global business and operations. He is an Executive Committee Member on the Clinical Trials Transformation Initiative, Board Member of Life Sciences Pennsylvania and former Chairman of the Board of the Association of Clinical Research Organizations (ACRO). During his career, Dr. Hubbard has been directly responsible for drug discovery and non-clinical pharmacology, clinical pharmacology, project management, product development optimization, commercial assessment of new chemical entities, and clinical development operations.

What is the salary of John Hubbard?

As the Independent Director of Agile Therapeutics Inc, the total compensation of John Hubbard at Agile Therapeutics Inc is $109,578. There are 7 executives at Agile Therapeutics Inc getting paid more, with Alfred Altomari having the highest compensation of $1,301,370.



How old is John Hubbard?

John Hubbard is 62, he's been the Independent Director of Agile Therapeutics Inc since 2017. There are 6 older and 10 younger executives at Agile Therapeutics Inc. The oldest executive at Agile Therapeutics Inc is Ajit Shetty, 73, who is the Independent Director.

What's John Hubbard's mailing address?

John's mailing address filed with the SEC is 500 COLLEGE ROAD EAST, SUITE 310, , PRINCETON, NJ, 08540.

Insiders trading at Agile Therapeutics Inc

Over the last 10 years, insiders at Agile Therapeutics Inc have traded over $2,369,944 worth of Agile Therapeutics Inc stock and bought 24,967,253 units worth $79,522,957 . The most active insiders traders include Advisors Llcperceptive Life..., Ab Investor a Capital Iii Llc Care Capita.... On average, Agile Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $1,032,678. The most recent stock trade was executed by Alfred Altomari on 26 August 2022, trading 50,000 units of AGRX stock currently worth $22,500.



What does Agile Therapeutics Inc do?

agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.



What does Agile Therapeutics Inc's logo look like?

Agile Therapeutics Inc logo

Agile Therapeutics Inc executives and stock owners

Agile Therapeutics Inc executives and other stock owners filed with the SEC include: